Valneva's Chikungunya Vaccine Shows Durable Antibody Persistence in All Age Groups

MT Newswires · 3d ago
01:32 AM EST, 11/10/2026 (MT Newswires) -- Valneva (VLA.PA) reported durable antibody persistence across all age groups from a single dose of its chikungunya vaccine, Ixchiq. The VLA1553-303 trial showed that 94% of the 221 healthy adults evaluable at year five maintained neutralizing antibody titers well above the seroresponse threshold, the Paris-listed specialty vaccine company said Tuesday. Adults aged 65 years and above demonstrated antibody persistence, which was comparable to the results in adults aged 18 to 64 years, with similar geometric mean titers and seroresponse rates. Valneva will continue to evaluate the participants and follow up for up to 10 years after vaccination.